Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2020-05-20 AGM Information
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Uchwały podjęte przez Zwyczajne Walne Zgromadzenie Celon Pharma S.A. w dniu 19 maja 2020 r. - Content (PL)
AGM Information Classification · 1% confidence The document text is very short (457 characters) and explicitly states that the Management Board ('Zarząd') is attaching the content of the resolutions ('treść uchwał') adopted by the Ordinary General Meeting ('Zwyczajne Walne Zgromadzenie Spółki') held on May 19, 2020. This structure—announcing the attachment of meeting resolutions—strongly suggests this is an announcement related to the AGM, rather than the full minutes or the AGM presentation itself. Since the content is the resolutions from the AGM, the most appropriate classification is AGM Information (AGM-R). It is not a general regulatory filing (RNS) because it is specific to the AGM, and it is not a voting result declaration (DVA) as it presents the resolutions themselves, not just the final tally.
2020-05-20 Polish
Uchwała Zwyczajnego Walnego Zgromadzenia Spółki w sprawie wypłaty dywidendy Podstawa prawna Art. 56 ust. 1 pkt 2 Ustawy o ofercie - informacje bieżące i okresowe - Content (PL)
Notice of Dividend Amount Classification · 1% confidence The document text explicitly states that the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie - ZWZ) held on May 19, 2020, passed a resolution regarding the distribution of the net profit for 2019. The resolution details the allocation of profit, specifically earmarking PLN 3,600,000.00 for dividend payment, setting the dividend record date (June 2, 2020), and the payment date (June 19, 2020). This content directly relates to the announcement of dividend amounts and details for shareholders, matching the definition for 'Notice of Dividend Amount' (DIV). Although it mentions the AGM, the core subject is the dividend decision, not general AGM materials or voting results.
2020-05-19 Polish
Sprawozdanie Rady Nadzorczej za rok 2019
Governance Information Classification · 1% confidence The document is the 'Annual Written Report of the Supervisory Board' (Roczne pisemne sprawozdanie Rady Nadzorczej) for Celon Pharma S.A. for the fiscal year 2019. It details the board's activities, assessment of the company's financial situation, internal controls, and recommendations regarding the approval of financial statements and profit distribution. This type of document is a standard component of corporate governance and annual reporting packages, specifically categorized as a Governance Information report (CGR) as it focuses on the oversight, internal rules, and board structure/performance rather than being the primary financial statement (10-K) or a simple announcement (RPA). FY 2019
2020-05-11 Polish
Uzupełnienie dokumentacji na Zwyczajne Walne Zgromadzenie Celon Pharma S.A. zwołane na dzień 19 maja 2020 roku - Content (PL)
Report Publication Announcement Classification · 1% confidence The document is a follow-up announcement (raport bieżący) regarding the Annual General Meeting (Zwyczajnego Walnego Zgromadzenia) scheduled for May 19, 2020. The core purpose of this specific announcement is to inform recipients that the Supervisory Board's Report (Sprawozdanie Rady Nadzorczej) for the 2019 financial year is attached for consideration at the AGM. Since the document itself is short (473 characters) and its primary function is to announce the publication/attachment of another document (the Supervisory Board's Report) related to the AGM agenda, it fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the context of announcing the availability of a specific report for an upcoming meeting, RPA is the most precise fit, as it signals the release of a report mentioned in the context of a corporate event.
2020-05-11 Polish
Celon Pharma Raport 2020Q1 Informacja Dodatkowa
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Raport kwartalny CELON PHARMA S.A. za I kwartał 2020' (Quarterly Report of Celon Pharma S.A. for Q1 2020). It contains detailed financial tables, including balance sheets and income statements for the specified period. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2020
2020-05-08 Polish
Celon Pharma Raport 2020Q1 Pozostałe Informacje
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly report ('Raport kwartalny') for Celon Pharma S.A. for Q1 2020. It contains detailed financial statements, balance sheets, cash flow analysis, management commentary on financial results, and disclosures regarding shareholding structures and corporate events. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2020
2020-05-08 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.